- Home
- GBIO vs SPKL Comparison
GBIO vs SPKL Comparison
Compare GBIO & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- SPKL
- Stock Information
- Founded
- GBIO 2016
- SPKL 2021
- Country
- GBIO United States
- SPKL United States
- Employees
- GBIO N/A
- SPKL N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- SPKL
- Sector
- GBIO Health Care
- SPKL
- Exchange
- GBIO Nasdaq
- SPKL Nasdaq
- Market Cap
- GBIO 145.5M
- SPKL 170.5M
- IPO Year
- GBIO 2020
- SPKL 2023
- Fundamental
- Price
- GBIO $2.18
- SPKL $10.46
- Analyst Decision
- GBIO Buy
- SPKL
- Analyst Count
- GBIO 4
- SPKL 0
- Target Price
- GBIO $7.50
- SPKL N/A
- AVG Volume (30 Days)
- GBIO 66.5K
- SPKL 26.4K
- Earning Date
- GBIO 08-07-2024
- SPKL 01-01-0001
- Dividend Yield
- GBIO N/A
- SPKL N/A
- EPS Growth
- GBIO N/A
- SPKL N/A
- EPS
- GBIO N/A
- SPKL 0.12
- Revenue
- GBIO $13,174,000.00
- SPKL N/A
- Revenue This Year
- GBIO $99.36
- SPKL N/A
- Revenue Next Year
- GBIO N/A
- SPKL N/A
- P/E Ratio
- GBIO N/A
- SPKL $85.74
- Revenue Growth
- GBIO 1397.05
- SPKL N/A
- 52 Week Low
- GBIO $0.86
- SPKL $10.07
- 52 Week High
- GBIO $4.83
- SPKL $11.35
- Technical
- Relative Strength Index (RSI)
- GBIO 38.71
- SPKL 60.73
- Support Level
- GBIO $2.26
- SPKL $10.45
- Resistance Level
- GBIO $2.49
- SPKL $10.46
- Average True Range (ATR)
- GBIO 0.23
- SPKL 0.01
- MACD
- GBIO -0.03
- SPKL -0.00
- Stochastic Oscillator
- GBIO 1.85
- SPKL 33.33
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.